Testing Against Ordered Alternatives for Censored Survival Data
删失生存数据中有序备择假设的检验AI 解读 ↓
本页整理公开书目信息,不生成学术质量评分。AI 解读根据题名及所注明的摘要或原文片段生成,未完成全文核验,可能有误;具体假设、证明与结论请核对原文。摘要保留来源文本,未经模型改写。
DOI 首次登记不等于接收或发表日期。部分更正、评论等条目没有独立摘要;缺少可靠材料时保留待补状态。
引用量采用 OpenAlex 单条关联记录,不合计多个记录;关联记录可能包含正式发表版本,不等于此版本单独引用。缺失不视为零,引用指标不代表论文质量。
关注作者按书目中的完整姓名匹配,同名和姓名变体需人工辨别。相关论文先按共享细分方向和具体方法排列,再参考通用方法与发表日期。
AI 根据所提供的论文材料归类:摘要研究删失生存数据的有序检验,未明确涉及因果识别或给定分类中的其他专门方向。
反馈分类问题删失生存数据中有序备择假设的检验AI 解读 ↓
正在核对关联版本…
正在核对对应版本的资源…
In animal carcinogenesis experiments or comparative clinical trials where the r groups correspond to increasing dosages of an agent or an increasing number of additional modalities and the primary outcome is time to a certain event (e.g., tumor occurrence, death) T, ordered alternatives of the form H1 : S1 ≤ S2 ≤ · · · ≤ Sr , where Si(t) = Pr (Ti > t) is the survival function for group are of special interest. Using the counting process formulation of the problem and generalizing earlier results, we show that the class of all two-sample weighted logrank statistics can be extended to test specifically for ordered alternatives. Ordered versions of the Gehan-Wilcoxon, unweighted logrank, and Peto–Prentice–Wilcoxon tests are investigated in detail. Asymptotic relative efficiencies under Lehmann and scale alternatives are evaluated analytically and numerically among these three tests and against Tarone's trend test (1975) for Weibull, gamma, and lognormal survival distributions. Effects of censoring and unequal group sizes are also explored. This class of tests has the advantage of having an asymptotic X2 (1) distribution, as opposed to the D distribution for the test proposed by Mau (1988). They can be easily calculated from modifying existing programs for two-sample weighted logrank tests. The ordered versions of the logrank test and the Peto–Prentice–Wilcoxon test are particularly recommended for their versatility under a variety of situations. The use of the tests is illustrated with data from a carcinogenesis experiment and from a colon cancer trial.